The OncoAlert Weekly Round Up Covering April 4-10, 2025

Dear Colleagues,

Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:

Prognostic implications of risk definitions from the monarchE and NATALEE trial

https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette

Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer

https://link.springer.com/article/10.1007/s10549-025-07685-8?utm_content=buffer1d9c4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial

https://www.nature.com/articles/s41591-025-03579-w

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1) 

https://nejm.org/doi/full/10.1056/NEJMoa2407934

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer

https://www.nature.com/articles/s41467-025-58435-9

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

https://www.annalsofoncology.org/article/S0923-7534(25)00130-9/abstract